Alimera Sciences (NASDAQ:ALIM – Get Free Report) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Thursday.
Separately, Maxim Group started coverage on shares of Alimera Sciences in a research report on Monday, March 25th. They issued a “buy” rating and a $10.00 price objective on the stock.
Alimera Sciences Stock Down 1.3 %
ALIM stock traded down $0.05 during midday trading on Thursday, reaching $3.90. 140,777 shares of the company were exchanged, compared to its average volume of 84,681. The company has a debt-to-equity ratio of 1.40, a quick ratio of 2.31 and a current ratio of 2.39. Alimera Sciences has a 1-year low of $1.56 and a 1-year high of $4.38. The stock’s 50-day simple moving average is $3.77 and its 200 day simple moving average is $3.57. The company has a market cap of $204.17 million, a price-to-earnings ratio of -1.81 and a beta of 1.18.
Alimera Sciences (NASDAQ:ALIM – Get Free Report) last announced its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.09). The business had revenue of $26.31 million for the quarter, compared to analysts’ expectations of $25.10 million. Alimera Sciences had a negative return on equity of 130.90% and a negative net margin of 24.93%. During the same quarter last year, the business posted ($0.54) earnings per share. On average, equities analysts forecast that Alimera Sciences will post 0.03 earnings per share for the current year.
Institutional Investors Weigh In On Alimera Sciences
Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Alimera Sciences by 342.4% in the fourth quarter. Vanguard Group Inc. now owns 648,954 shares of the biopharmaceutical company’s stock worth $2,803,000 after purchasing an additional 502,268 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Alimera Sciences in the fourth quarter worth $86,000. Balyasny Asset Management L.P. bought a new position in shares of Alimera Sciences in the fourth quarter worth $173,000. Stonepine Capital Management LLC grew its stake in shares of Alimera Sciences by 0.4% in the fourth quarter. Stonepine Capital Management LLC now owns 3,999,459 shares of the biopharmaceutical company’s stock worth $17,278,000 after purchasing an additional 15,773 shares in the last quarter. Finally, Northern Trust Corp bought a new position in shares of Alimera Sciences in the fourth quarter worth $61,000. 99.83% of the stock is owned by institutional investors and hedge funds.
Alimera Sciences Company Profile
Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).